References
- Alsoufi, B., et al., 2015. Outcomes and risk factors for heart transplantation in children with end-stage cardiomyopathy. European journal of cardio-thoracic surgery, 9, 85–92.
- Calvert, C.A., et al., 1997. Signalment, survival, and prognostic factors in Doberman Pinschers with end‐stage cardiomyopathy. Journal of veterinary internal medicine, 11 (6), 323–326.
- Devaux, Y., et al., 2015. Long noncoding RNAs in cardiac development and ageing. Nature reviews cardiology, 12 (7), 415–425.
- Franklin, S.S., et al., 2001. Does the relation of blood pressure to coronary heart disease risk change with aging?: The Framingham Heart Study. Circulation, 103 (9), 1245–1249.
- Go, A.S., et al., 2014. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation, 129 (3), 399–410.
- Gummert, J.F., et al., 2003. Mitral valve repair in patients with end stage cardiomyopathy: who benefits? European journal of cardio-thoracic surgery, 23 (6), 1017–1022.
- Huang, Z.P., et al., 2016. Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. Cardiovascular research, 112 (2), 543–554.
- Kumarswamy, R., et al., 2014. The circulating long non-coding RNA LIPCAR predicts survival in heart failure patients. Circulation research, 14, 1569–1575.
- Li, X., et al., 2016. lncRNA H19/miR-675 axis regulates cardiomyocyte apoptosis by targeting VDAC1 in diabetic cardiomyopathy. Scientific reports, 6 (1), 36340.
- Liu, C.Y., et al., 2018. LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription. Nature communications, 9 (1), 29–35.
- Lu, L., et al., 2016. Epigenetic silencing of miR-218 by the lncRNA CCAT1, acting via BMI1, promotes an altered cell cycle transition in the malignant transformation of HBE cells induced by cigarette smoke extract. Toxicology and applied pharmacology, 304, 30–41.
- Mayfield, R.D., 2017. Emerging roles for ncRNAs in alcohol use disorders. Alcohol, 60, 31–39.
- Mattick, J.S., and Makunin, I.V., 2006. Non-coding RNA. Human molecular genetics, 5, 17–29.
- Mercer, T.R., Dinger, M.E., and Mattick, J.S., 2009. Long non-coding RNAs: insights into functions. Nature reviews genetics, 10 (3), 155–159.
- Sin, N.L., Yaffe, K., and Whooley, M.A., 2015. Depressive symptoms, cardiovascular disease severity, and functional status in older adults with coronary heart disease: the heart and soul study. Journal of the American geriatrics society, 3, 8–15.
- Uchida, S., and Dimmeler, S., 2015. Long noncoding RNAs in cardiovascular diseases. Circulation research, 116 (4), 737–7505.
- Vatta, M., et al., 2002. Molecular remodelling of dystrophin in patients with end-stage cardiomyopathies and reversal in patients on assistance-device therapy. The lancet, 359 (9310), 936–941.
- Wexler, R., et al., 2009. Cardiomyopathy: an overview. American family physician, 79 (9), 778–784.
- Yang, W., et al., 2015. Microarray profiling of long non-coding RNA (lncRNA) associated with hypertrophic cardiomyopathy. BMC cardiovascular disorders, 15 (1), 62–67.
- Yavari, M., and Becker, R.C., 2009. Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. Journal of thrombosis and thrombolysis, 27 (1), 95–104.